Literature DB >> 15238219

Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.

Catherine Le Jossic-Corcos1, Sandrine Duclos, Leyla C Ramirez, Isabelle Zaghini, Grégory Chevillard, Pascal Martin, Thierry Pineau, Paulette Bournot.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARalpha) activation by fibrates controls expression of several genes involved in hepatic cholesterol metabolism. Other genes could be indirectly controlled in response to changes in cellular cholesterol availability. To further understand how fibrates may affect cholesterol synthesis, we investigated in parallel the changes in the metabolic pathways contributing to cholesterol homeostasis in liver. Ciprofibrate increased HMG-CoA reductase and FPP synthase mRNA levels in rat hepatocytes, together with cholesterogenesis from [(14)C] acetate and [(3)H] mevalonate. The up-regulation observed in fenofibrate- and WY-14,643-treated mice was abolished in PPARalpha-null mice, showing an essential role of PPARalpha. Among the three sterol regulatory element-binding protein (SREBP) mRNA species, only SREBP-1c level was significantly increased. In ciprofibrate-treated hepatocytes, cholesterol efflux was decreased, in parallel with cholesteryl ester storage and bile acids synthesis. As expected, AOX expression was strongly induced, supporting evidence of the peroxisome proliferation. Taken together, these results show that fibrates can cause cholesterol depletion in hepatocytes, possibly in part as a consequence of an important requirement of cholesterol for peroxisome proliferation, and increase cholesterogenesis by a compensatory phenomenon afterwards. Such cholesterogenesis regulation could occur in vivo, in species responsive to the peroxisome proliferative effect of PPARalpha ligands.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238219     DOI: 10.1016/j.bbalip.2004.04.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha).

Authors:  Ana Fernández-Alvarez; María Soledad Alvarez; Raúl Gonzalez; Carme Cucarella; Jordi Muntané; Marta Casado
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

2.  Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.

Authors:  Catherine Le Jossic-Corcos; Céline Gonthier; Isabelle Zaghini; Emmanuelle Logette; Ishaiahu Shechter; Paulette Bournot
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

3.  Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.

Authors:  Fang Yan; Qi Wang; Chao Xu; Mingfeng Cao; Xiaoming Zhou; Tingting Wang; Chunxiao Yu; Fei Jing; Wenbin Chen; Ling Gao; Jiajun Zhao
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

4.  Inhibitors of Fatty Acid Synthesis Induce PPAR α -Regulated Fatty Acid β -Oxidative Genes: Synergistic Roles of L-FABP and Glucose.

Authors:  Huan Huang; Avery L McIntosh; Gregory G Martin; Anca D Petrescu; Kerstin K Landrock; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  PPAR Res       Date:  2013-02-26       Impact factor: 4.964

5.  Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor.

Authors:  Z Huang; X Zhou; A C Nicholson; A M Gotto; D P Hajjar; J Han
Journal:  Br J Pharmacol       Date:  2008-08-18       Impact factor: 8.739

6.  Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.

Authors:  Mehmet Cindoruk; Mustafa Kerem; Tarkan Karakan; Bulent Salman; Okan Akin; Murat Alper; Ozlem Erdem; Selahattin Unal
Journal:  BMC Gastroenterol       Date:  2007-11-28       Impact factor: 3.067

7.  Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle.

Authors:  Sefaa Al-aryahi; Danielle Kamato; Robel Getachew; Wenhua Zheng; Simon J Potocnik; Neale Cohen; Daniel Guidone; Narin Osman; Peter J Little
Journal:  Cardiovasc Diabetol       Date:  2014-04-15       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.